Learn More
PURPOSE To evaluate the efficacy of adding lapatinib to capecitabine and oxaliplatin (CapeOx) in patients with previously untreated human epidermal growth factor receptor 2 (HER2) -amplified advanced(More)
LBA4001 Background: HER2 amplification is common in upper GI tract (UGIT) adenocarcinomas and inhibition improves clinical outcomes. Lapatinib ditosylate (L), a dual anti EGFR and anti HER2 tyrosine(More)
G.G. Steger1, A. Dominguez2, O. Switsers3, N. Dobrovolskaya4, F. Giotta5, I. Glogowska6, N. Tubiana-Mathieu7, M. Pecherstorfer8, A. Ardizzoia9, P. Bougnoux10, M. Blasinska-Morawiec11, C. Veyret12, S.(More)